Literature DB >> 14767735

Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients.

Takanori Uemura1, Kenji Hibi, Tetsuya Kaneko, Shin Takeda, Soichiro Inoue, Osamu Okochi, Tetsuro Nagasaka, Akimasa Nakao.   

Abstract

BACKGROUND: In pancreatic cancers, K-ras mutations have been found frequently (80%-100%), and they could be a good marker to detect tumor DNA in the plasma. Several studies have indicated that polymerase chain reaction/restriction fragment length polymorphism (PCR/RFLP) analysis of K-ras mutation was a useful method for the detection of hepatic and lymph node metastasis of pancreatic cancer. However, this method sometimes exhibited false-positive results, and the rate of K-ras mutation might thus be overestimated in these tissues. To diagnose pancreatic cancer correctly at an early stage, we attempted to detect tumor DNA in the plasma of pancreatic cancer patients using a more sensitive and specific method.
METHODS: We examined 28 pancreatic cancer patients using a sensitive mutation-specific mismatch ligation assay for K-ras gene mutations in primary tumors and paired plasma samples.
RESULTS: K-ras gene mutations were detected in 26 of the 28 (93%) pancreatic cancers. We also found the same mutations in 9 of these 26 (35%) patients in their plasma DNA. This mutation was found even in the plasma of patients with TNM stage II cancer.
CONCLUSIONS: Genetic alterations present in the tumors of pancreatic cancer patients can be detected in their plasma, and this approach is potentially applicable for cancer screening and the monitoring of this deadly disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14767735     DOI: 10.1007/s00535-003-1245-1

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  28 in total

Review 1.  Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.

Authors:  Francesca Riva; Oleksii I Dronov; Dmytro I Khomenko; Florence Huguet; Christophe Louvet; Pascale Mariani; Marc-Henri Stern; Olivier Lantz; Charlotte Proudhon; Jean-Yves Pierga; Francois-Clement Bidard
Journal:  Mol Oncol       Date:  2016-01-22       Impact factor: 6.603

Review 2.  Oncological problems in pancreatic cancer surgery.

Authors:  Akimasa Nakao; Tsutomu Fujii; Hiroyuki Sugimoto; Naohito Kanazumi; Shuji Nomoto; Yasuhiro Kodera; Soichiro Inoue; Shin Takeda
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

3.  K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking.

Authors:  Li Jiao; Jijiang Zhu; Manal M Hassan; Douglas B Evans; James L Abbruzzese; Donghui Li
Journal:  Pancreas       Date:  2007-01       Impact factor: 3.327

4.  Regulation of pancreatic cancer growth by superoxide.

Authors:  Juan Du; Elke S Nelson; Andrean L Simons; Kristen E Olney; Justin C Moser; Hannah E Schrock; Brett A Wagner; Garry R Buettner; Brian J Smith; Melissa L T Teoh; Ming-Sound Tsao; Joseph J Cullen
Journal:  Mol Carcinog       Date:  2012-03-05       Impact factor: 4.784

5.  An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis.

Authors:  Hue H Luu; Quan Kang; Jong Kyung Park; Weike Si; Qing Luo; Wei Jiang; Hong Yin; Anthony G Montag; Michael A Simon; Terrance D Peabody; Rex C Haydon; Carrie W Rinker-Schaeffer; Tong-Chuan He
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

6.  High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.

Authors:  K Allenson; J Castillo; F A San Lucas; G Scelo; D U Kim; V Bernard; G Davis; T Kumar; M Katz; M J Overman; L Foretova; E Fabianova; I Holcatova; V Janout; F Meric-Bernstam; P Gascoyne; I Wistuba; G Varadhachary; P Brennan; S Hanash; D Li; A Maitra; H Alvarez
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

7.  Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.

Authors:  B Lee; L Lipton; J Cohen; J Tie; A A Javed; L Li; D Goldstein; M Burge; P Cooray; A Nagrial; N C Tebbutt; B Thomson; M Nikfarjam; M Harris; A Haydon; B Lawrence; D W M Tai; K Simons; A M Lennon; C L Wolfgang; C Tomasetti; N Papadopoulos; K W Kinzler; B Vogelstein; P Gibbs
Journal:  Ann Oncol       Date:  2019-09-01       Impact factor: 32.976

Review 8.  The complex landscape of pancreatic cancer metabolism.

Authors:  Cristovão Marques Sousa; Alec C Kimmelman
Journal:  Carcinogenesis       Date:  2014-04-17       Impact factor: 4.944

9.  Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.

Authors:  C Salek; L Benesova; M Zavoral; V Nosek; L Kasperova; M Ryska; R Strnad; E Traboulsi; M Minarik
Journal:  World J Gastroenterol       Date:  2007-07-21       Impact factor: 5.742

Review 10.  Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes.

Authors:  Xu Zhang; Si Shi; Bo Zhang; Quanxing Ni; Xianjun Yu; Jin Xu
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.